Metabolism open最新文献

{"title":"Receptor tyrosine kinases and steroid hormone receptors in breast cancer: Review of recent evidences","authors":"Awgichew Behaile Teklemariam ,&nbsp;Zelalem Tilahun Muche ,&nbsp;Melaku Mekonnen Agidew ,&nbsp;Anemut Tilahun Mulu ,&nbsp;Edgeit Abebe Zewde ,&nbsp;Nega Dagnew Baye ,&nbsp;Dagnew Getnet Adugna ,&nbsp;Lemlemu Maru ,&nbsp;Teklie Mengie Ayele","doi":"10.1016/j.metop.2024.100324","DOIUrl":"10.1016/j.metop.2024.100324","url":null,"abstract":"<div><div>Breast cancer development and progression are driven by intricate networks involving receptor tyrosine kinases (RTKs) and steroid hormone receptors specifically estrogen receptor (ER) and progesterone receptor (PR). This review examined roles of each receptor under normal physiology and in breast cancer, and explored their multifaceted interactions via signaling pathways, focusing on their contributions to breast cancer progression. Since defining the mechanism by which these two-receptor mediated signaling pathways cooperate is essential for understanding breast cancer progression, we discussed the mechanisms of cross-talk between RTKs and ER and PR and their potential therapeutic implications as well. The crosstalk between RTKs and steroid hormone receptors (ER and PR) in breast cancer can influence the disease's progression and treatment outcomes. Therefore, understanding the functions of the aforementioned receptors and their interactions is crucial for developing effective therapies.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"24 ","pages":"Article 100324"},"PeriodicalIF":0.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Missed opportunities in statin therapy: A critical appraisal of prescription practices in sub-Saharan Africa","authors":"Stephan Mayntz,&nbsp;Rose Peronard","doi":"10.1016/j.metop.2024.100323","DOIUrl":"10.1016/j.metop.2024.100323","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"24 ","pages":"Article 100323"},"PeriodicalIF":0.0,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142433041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tea intake and non-alcoholic fatty liver disease risk: A two-sample Mendelian randomization study","authors":"Cuncun Lu ,&nbsp;Lixin Ke ,&nbsp;Alexios-Fotios A. Mentis ,&nbsp;Qiang Zhang ,&nbsp;Ziyi Wang ,&nbsp;Zhifei Wang","doi":"10.1016/j.metop.2024.100322","DOIUrl":"10.1016/j.metop.2024.100322","url":null,"abstract":"<div><h3>Background</h3><div>Non-alcoholic fatty liver disease (NAFLD) is a major global health problem due to its great disease and economic burdens. Tea is a popular beverage consumed by billions of people.</div><div>globally owing to its health benefits. However, the evidence regarding the association between tea intake and NAFLD risk is inconsistent.</div></div><div><h3>Objective</h3><div>To examine the genetically predicted causal association between tea intake and NAFLD risk using the two-sample Mendelian randomization (MR) method.</div></div><div><h3>Methods</h3><div>Single‐nucleotide polymorphisms (SNPs) strongly associated with tea intake were obtained from a large dataset (N = 447,485) in the UK biobank, and summary‐level genetic data for NAFLD (2,275 cases and 375,002 controls) were collected from the FinnGen consortium. The two-sample MR method was used to investigate the causal association between tea intake and NAFLD risk. The random‐effects inverse‐variance weighted (IVW) was used as the primary approach for estimating the causal effect, and MR Egger, weighted median, simple mode, and weighted mode were used to verify the robustness of the primary results.</div></div><div><h3>Results</h3><div>Twenty-four valid SNPs were selected as the instrumental variables for tea intake. The IVW results indicated that tea intake was not causally associated with NAFLD risk (Odds ratio: 1.48; 95 % confidence interval: 0.64, 3.43; <em>p</em> = 0.364); moreover, the results from other methods were consistent with this finding. A leave-one-out analysis further demonstrated the robustness of our results. No evidence of heterogeneity, outliers, or horizontal pleiotropy was found.</div></div><div><h3>Conclusion</h3><div>Our results do not support tea intake being causally associated with a decreased risk of NAFLD.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"24 ","pages":"Article 100322"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142327334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum and urinary levels of MIF, CD74, DDT and CXCR4 among patients with type 1 diabetes mellitus, type 2 diabetes and healthy individuals: Implications for further research","authors":"Katia Mangano ,&nbsp;Aristidis Diamantopoulos ,&nbsp;Natalia G. Vallianou ,&nbsp;Theodora Stratigou ,&nbsp;Fotis Panagopoulos ,&nbsp;Dimitris Kounatidis ,&nbsp;Maria Dalamaga ,&nbsp;Paolo Fagone ,&nbsp;Ferdinando Nicoletti","doi":"10.1016/j.metop.2024.100320","DOIUrl":"10.1016/j.metop.2024.100320","url":null,"abstract":"<div><h3>Background</h3><p>Macrophage migration inhibitory factor (MIF) is a highly conserved cytokine with pleiotropic properties, mainly pro-inflammatory. MIF seems to exert its pro-inflammatory features by binding to its transmembrane cellular receptor CD74. MIF also has CXCR4, which acts as a co-receptor in this inflammatory process. Apart from MIF, D-dopachrome tautomerase (DDT) or MIF2, which belongs to the MIF superfamily, also binds to receptor CD74. Therefore, these molecules, MIF, CD74, DDT and CXCR4 are suggested to work together orchestrating an inflammatory process. Diabetes mellitus is characterised by chronic low-grade inflammation. Therefore, the aim of the present study was to evaluate serum and urinary levels of the aforementioned molecules among patients with type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) and among healthy controls.</p></div><div><h3>Methods</h3><p>We enrolled 13 patients with T1DM, 74 patients with T2DM and 25 healthy individuals as controls. Levels of CD74, CXCR4, DDT, and MIF were measured using ELISA Kits according to the manufacturer's instructions.</p></div><div><h3>Results</h3><p>We documented increased serum MIF levels together with higher urinary CD74 levels among patients with T1DM, when compared to patients with T2DM and healthy adults. In particular, patients with T1DM showed significantly increased levels of MIF compared to T2DM (p = 0.011) and healthy controls (p = 0.0093). CD74 in urine were significantly higher in patients with T1DM compared to those affected with T2DM (p = 0.0302) and healthy group (p = 0.0099). On the contrary, serum CD74 were similar among the three groups. No statistical differences were identified in CXCR4 levels both in serum and in urine of all groups. Patients with T2DM and overweight/obesity had increased urinary levels of CD74, when compared to lean patients with T2DM.</p></div><div><h3>Conclusion</h3><p>The increased serum MIF levels and urinary CD74 levels among patients with T1DM may be attributed to the autoimmune milieu, which characterises patients with T1DM, when compared to patients with T2DM. These two findings merit further attention as they could pave the way for further research regarding the potential beneficial effects of inhibitors of MIF among patients with T1DM, especially in the early stages of T1DM. Finally, the role of inhibitors of MIF could be further explored in the context of obesity among patients with T2DM.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"24 ","pages":"Article 100320"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000525/pdfft?md5=6cabb9a4c9b9616d76285a67013c8432&pid=1-s2.0-S2589936824000525-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142239008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials","authors":"Eric Pasqualotto ,&nbsp;Rafael Oliva Morgado Ferreira ,&nbsp;Matheus Pedrotti Chavez ,&nbsp;Alexandre Hohl ,&nbsp;Marcelo Fernando Ronsoni ,&nbsp;Tales Pasqualotto ,&nbsp;Francisco Cezar Aquino de Moraes ,&nbsp;Larissa Hespanhol ,&nbsp;Janine Midori Figueiredo Watanabe ,&nbsp;Carine Lütkemeyer ,&nbsp;Simone van de Sande-Lee","doi":"10.1016/j.metop.2024.100321","DOIUrl":"10.1016/j.metop.2024.100321","url":null,"abstract":"<div><h3>Aim</h3><p>To assess the effects of once-weekly subcutaneous retatrutide on weight and metabolic markers and the occurrence of side effects in patients with overweight, obesity and/or type 2 diabetes (T2D).</p></div><div><h3>Methods</h3><p>PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched for placebo-controlled, randomized clinical trials (RCTs) published up until February 23, 2024. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) for binary endpoints were computed, with 95 % confidence intervals (CIs).</p></div><div><h3>Results</h3><p>A total of three studies were included, comprising 640 patients, of whom 510 were prescribed retatrutide. Compared with placebo, retatrutide significantly reduced body weight (WMD -10.66 kg; 95 % CI -17.63, −3.69), body mass index (WMD -4.53 kg/m²; 95 % CI -7.51, −1.55), and waist circumference (WMD -6.61 cm; 95 % CI -13.17, −0.05). In addition, retatrutide significantly increased the proportion of patients who achieved a weight reduction of ≥5 % (RR 2.92; 95 % CI 2.17–3.93), ≥10 % (RR 9.32; 95 % CI 4.56–19.06), ≥15 % (RR 18.40; 95 % CI 6.00–56.42), and ≥20 % (RR 16.61; 95 % CI 4.17–66.12).</p></div><div><h3>Conclusions</h3><p>In this meta-analysis, the use of once-weekly subcutaneous retatrutide was associated with a significant reduction in body weight and improvement of metabolic markers in patients with overweight, obesity and/or T2D, compared with placebo, with an increase in non-severe gastrointestinal and hypersensitivity adverse events. Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-weekly subcutaneous retatrutide over the long term.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"24 ","pages":"Article 100321"},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000537/pdfft?md5=ab065d5e73436eb122ff0c4b8cdd58b0&pid=1-s2.0-S2589936824000537-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142239066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study","authors":"Yuji Kawaguchi,&nbsp;Yuriko Hajika,&nbsp;Narumi Ashida,&nbsp;Maho Rinka,&nbsp;Chie Hamai,&nbsp;Koji Masumoto,&nbsp;Jun Sawa,&nbsp;Kenji Hamazaki,&nbsp;Yasuro Kumeda","doi":"10.1016/j.metop.2024.100318","DOIUrl":"10.1016/j.metop.2024.100318","url":null,"abstract":"<div><h3>Aim/introduction</h3><p>Early therapeutic interventions are necessary to reduce cardiovascular and renal composite endpoints in individuals with type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD). Clinical trials have shown that finerenone suppresses cardiovascular and renal composite endpoints by reducing the urinary albumin-to-creatinine ratio (UACR) and suppressing the decline in the Estimated Glomerular Filtration Rate (eGFR). However, the efficacy and safety of finerenone in real-world clinical practice remain unclear. This study aimed to evaluate the reduction in the UACR as an efficacy endpoint as well as changes in eGFR and serum potassium levels as safety endpoints before and after finerenone administration.</p></div><div><h3>Materials and methods</h3><p>This retrospective observational study collected data from outpatients with T2DM and DKD upon initiation of finerenone treatment and 3 months after treatment. The primary efficacy endpoint was the change in the UACR from the start of finerenone treatment to after 3 months, while the primary safety endpoints were the changes in serum potassium levels and eGFR over the same period.</p></div><div><h3>Results</h3><p>The mean UACR significantly decreased from 668.6 mg/gCr at the start of finerenone treatment to 367.8 mg/gCr after 3 months (p &lt; 0.001). Contrastingly, serum potassium levels, eGFRs, systolic and diastolic blood pressures, body mass indices, and HbA1c levels showed no significant changes between treatment initiation and 3 months post-treatment (all p &gt; 0.05).</p></div><div><h3>Conclusions</h3><p>In individuals with T2DM and DKD, finerenone treatment significantly reduced the UACR, with no post-treatment changes in potassium levels or eGFRs.</p></div><div><h3>Trial registration</h3><p>This trial was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN000054821).</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"24 ","pages":"Article 100318"},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000501/pdfft?md5=bbd957e47dab3060ea67fc6216184cc1&pid=1-s2.0-S2589936824000501-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluations of the in vitro and in vivo antidiabetic activity of 70 % ethanolic fruit extracts of Rosa abyssinica","authors":"Mohammed Ahmed Abdul ,&nbsp;Akeberegn Gorems Ayele ,&nbsp;Frehiwot Teka ,&nbsp;Worku Gemchu ,&nbsp;Workineh Shibeshi","doi":"10.1016/j.metop.2024.100317","DOIUrl":"10.1016/j.metop.2024.100317","url":null,"abstract":"<div><h3>Background</h3><p>Diabetes mellitus is becoming major health challenge with continually increasing burden. High costs of conventional medicines and numerous side effects associated with them, on the other hand, easy availability and accessibility of traditional herbal medicines calls upon experimental investigations to validate their effect on lowering blood glucose level.</p></div><div><h3>Methods</h3><p>The dried fruit of <em>Rosa abyssinica</em> was macerated with 70 % ethanol and the extract's <em>in vitro</em> antidiabetic activity was investigated using dinitrosalisylic acid method for alpha amylase inhibitory activity. Furthermore, the <em>in vivo</em> hypoglycemic and Antihyperglycemic effects of various doses of the extract (100, 200 and 400 mg/kg) was determined on normoglycemic, glucose loaded (1500 mg/kg) and Streptozotocine (180 mg/kg)-induced diabetic mice models.</p></div><div><h3>Results</h3><p>The acute oral toxicity study revealed the plant showed no toxic effect on swiss albino mice at 2000 mg/kg. The <em>in vitro</em> alpha amylase inhibitory activity study showed that the extract has comparable IC50 value of 21.37 ± 4.252 μg/ml with the standard drug acarbose (IC50 value of 26.72 ± 3.59 μg/ml). On the other hand, in normal mice, none of the dose levels except at 400 mg/kg significantly reduces blood glucose level. This is in contrast to the oral glucose tolerance test, which the extract produced significant reduction at 60, 90 and 120 min following glucose challenge. The 70 % ethanolic fruit extracts of <em>Rosa abyssinica</em> also experienced profound antidiabetic activity in streptozotocin-induced diabetic model. In the single-dose study, both RAFE200 and RAFE400 demonstrated a significant (P˂0.05) reduction in blood glucose levels at 1, 2, 3, and 4 h. Similarly, in the repeated-dose study, RAFE200 and RAFE400 not only significantly reduced blood glucose levels but also produced a notable improvement in animal body weight.</p></div><div><h3>Conclusion</h3><p>The 70 % ethanolic fruit extracts of <em>Rosa abyssinica</em> have shown significant <em>in vitro</em> alpha amylase inhibition effect and an <em>in vivo</em> blood glucose level lowering effects in diabetic mice.</p><p>Therefore, this study supports the traditional use of <em>Rosa abyssinica</em> in the management of diabetes mellitus.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"23 ","pages":"Article 100317"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000495/pdfft?md5=02fdeae342e60027fb61c9715b9db529&pid=1-s2.0-S2589936824000495-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How do gamified digital therapeutics work on obesity self-management?","authors":"Xuejuan Zhu ,&nbsp;Shuneng Gu ,&nbsp;Jian Li","doi":"10.1016/j.metop.2024.100314","DOIUrl":"10.1016/j.metop.2024.100314","url":null,"abstract":"<div><p>Obesity management can effectively reduce the risks and complications associated with obesity and improve the quality of life of patients. After assessing the advantages and limitations of various obesity management approaches, self-management has been strongly recommended due to the advantages of minimal side effects and lower costs compared to treatment via drugs and surgery. However, successfully implementing lifestyle intervention strategies requires scientific guidance and strong determination. With the development of electronic and information technology, lifestyle intervention has transformed considerably. A new concept, called Gamified Digital Therapeutics (GDTx), represents a gaming format with Digital Therapeutics (DTx). It can effectively enhance patient compliance and accessibility to chronic disease management. Here, we review recent studies on the application of GDTx for the self-management of obesity and discuss three aspects surrounding its completion rates, satisfaction levels, and effectiveness. In contrast to traditional approaches to obesity self-management, implementing GDTx effectively corrects unhealthy dietary and lifestyle habits, markedly enhancing the dissemination of nutritional and exercise-related health knowledge. Of particular significance is the evident improvement in the adherence of obese patients to weight loss programs. Despite numerous studies indicating that GDTx may offer an effective solution for obesity self-management, there are still several limitations in the medicalization of GDTx for self-management of obesity. This review aimed to provide a reference for subsequent studies and promote the widespread application of GDTx in obesity self-management to help reduce the obesity rate and alleviate the burden on obese patients.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"23 ","pages":"Article 100314"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S258993682400046X/pdfft?md5=fe36abb0baf8025be5b8b79b561eec65&pid=1-s2.0-S258993682400046X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142149206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loss of insulin receptor isoform B impairs proinsulin processing in pancreatic β cells","authors":"Hanrui Yin,&nbsp;Suzhen Chen,&nbsp;Junli Liu","doi":"10.1016/j.metop.2024.100309","DOIUrl":"10.1016/j.metop.2024.100309","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"23 ","pages":"Article 100309"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000410/pdfft?md5=ec1e6893f04d1bb32b18123b9ac357c7&pid=1-s2.0-S2589936824000410-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142232073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Once-weekly insulin icodec versus once-daily long-acting insulins for type 2 diabetes mellitus: Systematic review and meta-analysis” [Metabolism Open, 22 (2024) 100285]","authors":"Sandro Augusto Goncalves Ribeiro ,&nbsp;Matheus Pedrotti Chavez ,&nbsp;Larissa Calixto Hespanhol ,&nbsp;Caroline Cristine Almeida Balieiro ,&nbsp;Eric Pasqualotto ,&nbsp;Rodrigo Ribeiro e Silva ,&nbsp;Mateus Gauza ,&nbsp;João Roberto de Sa","doi":"10.1016/j.metop.2024.100308","DOIUrl":"10.1016/j.metop.2024.100308","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"23 ","pages":"Article 100308"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936824000409/pdfft?md5=686e5eb801a53d7a2d7adfd9d88855b2&pid=1-s2.0-S2589936824000409-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142232611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}